



European Society for Blood and Marrow Transplantation

NEWSletter2013

CHRONIC MALIGNANCIES WORKING PARTY (CMWP)

Dear Friends and Colleagues,

it is a great pleasure to inform you about the developments and achievement of the Chronic Malignancies Working Party (CMWP) in 2013.

This year posed a major challenge for our working party because of limited resources. The CMWP (formerly Chronic Leukemia Working Party) is one of the largest and one of the most productive WP within the EBMT.

Therefore to maintain high level of activities we had to enhance our efficacy by restructuring and standardizing the working flow of our projects. This was mainly elaborated by our data management: Anja van Biezen and our dedicated statisticians: Simona Iacobelli and Liesbeth de Wreede. This will (and already did!) strengthen and shorten the process from study proposal to publication.

The ongoing or recently closed prospective and non interventional studies (NIS) by the subcommittee CLL such as "Allogeneic SCT in CLL with del17p" and "Allogeneic SCT in P-TLL" and from the MDS subcommittee. "Iron overload prior allogeneic SCT" or "5-Aza vs allogeneic SCT in elderly pts with MDS" and from the MPN subcommittee: "TKI prior allogeneic SCT in CML" from the Plasma Cell Disorder Subcommittee. "Stem Cell mobilization in MM-CALM Study" and "Allogeneic SCT for Amyloidosis" are important contributions of our subcommittee to the scientific community. However, they will be only successful if EBMT members are continuously participating in such trial.

The entire CMWP would like to express their gratefulness to all EBMT members and centers for their strong support in sending additional data for retrospective studies and including patients into ongoing trials. A first international

education on how to integrate allogeneic SCT into the treatment of myelofibrosis and CML has been successful arranged in 2013, Hamburg/Germany.

To maintain and increase the scientific value of our retrospective studies an innovative data quality initiative has been launched by the CLL subcommittee, which has been now adapted also from other working parties and has been acknowledged by the EBMT board as one of the major tasks for the near future.

We'd like to encourage you to join our regular business meeting and educational events, submit proposals for retrospective and prospective studies, participate in lively discussions and exchange knowledge with colleagues and experts in the field.

Best wishes



email:
nkroeger@uke.de

Nicolaus Kröger

Chair of the CMWP
University Hamburg, CIC 614



email:
stefan.schoenland@med.uni-heidelberg.de

Stefan Schönland

Secretary of the CMWP
University Heidelberg, CIC 524

SAVE THE DATE

++ 2014 ++

31.1./1.2.2014

Business Meeting and educational Event (CLL) in Leiden/The Netherlands

Host: M. van Gelder and L. de Wreede

30.3.2014

Business Meeting during EBMT Annual Meeting: Milano/Italy

31.3.2014

CMWP: Working Party Session (16:00 - 17:30 h)
(at EBMT Annual Meeting) in Milano/Italy

12./13.9.2014

Business Meeting and Educational Event (MDS) in Lille/France
Host: Ibrahim Yakoub-Agha

Publications from CMWP in 2013

1. Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation. A Study of the MPN-Subcommittee of the CMWP of the EBMT.

Alchalby H, Zabelina T, Stübig T, van Biezen A, Bornhäuser M, Di Bartolomeo P, Beelen D, Cahn JY, Dreger P, Schroyens W, de Witte T, Olavarria E, Kröger N; for the CMWP of the EBMT.

Biol Blood Marrow Transplant. 2013 Nov 4. doi:pil: S1083-8791(13)00504-1. 10.1016/j.bbmt.2013.10.027. [Epub ahead of print]

2. Improved PFS after autologous stem cell transplantation does not translate into better Quality of Life in CLL: lessons from the randomized EBMT-Intergroup study.

de Wreede LC, Watson M, van Os M, Milligan D, van Gelder M, Michallet M, Dreger P, Dearden CE, Homewood J, Dupuis J, Leporrier M, Karas M, Corront B, Baerlocher GM, Herr W, Choquet S, Niederwieser DW, Sutton L, Kröger N, de Witte TM, Schetelig J.

Am J Hematol. 2013 Oct 9. doi: 10.1002/ajh.23610. [Epub ahead of print]

3. Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly pts with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data.

Brand R, Putter H, van Biezen A, Niederwieser D, Martino R, Mufti G, Onida F, Symeonidis A, Schmid C, Garderet L, Robin M, van Gelder M, Finke J, Bornhäuser M, Kobbe G, Germing U, de Witte T, Kröger N.

PLoS One. 2013 Oct 7;8(10):e74368. doi: 10.1371/journal.pone.0074368

4. From nuclear to a global family: more donors for MDS.

Kröger N.

Blood. 2013 Sep 12;122(11):1848-50

5. Reduced intensity-conditioned allogeneic stem cell transplantation

for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation.

Auner HW, Szydlo R, van Biezen A, Iacobelli S, Gahrton G, Milpied N, Volin L, Janssen J, Nguyen Quoc S, Michallet M, Schoemans H, El Cheikh J, Petersen E, Guilhot F, Schönland S, Ahlberg L, Morris C, Garderet L, de Witte T, Kröger N.

Bone Marrow Transplant. 2013 Nov;48(11):1395-400. doi: 10.1038/bmt.2013.73. Epub 2013 May 27

6. Autologous / reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.

Gahrton G, Iacobelli S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Schönland S, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N; EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee.

Blood. 2013 Jun 20;121(25):5055-63. doi: 10.1182/blood-2012-11-469452. Epub 2013 Mar 12.

7. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.

Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T, Giagounidis A, Zohren F, Bruns I, Wolschke C, Rieger K, Fenk R, Germing U, Haas R, Kröger N, Kobbe G.

Leukemia. 2013 Jun;27(6):1229-35. doi: 10.1038/leu.2013.7. Epub 2013 Jan 14.

8. Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT.

Martino R, de Wreede L, Fiocco M, van Biezen A, von dem Borne PA, Hamladji RM, Volin L, Bornhäuser M, Robin M, Rocha V, de Witte T, Kröger N, Mohanty M; Acute Leukemia Working Party the subcommittee for Myelodysplastic Syndromes of the Chronic Malignancies Working Party of the European group for Blood Marrow Transplantation Group (EBMT).

Bone Marrow Transplant. 2013 Jun;48(6):761-70. doi: 10.1038/bmt.2012.236. Epub 2012 Dec 3.

9. Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia.

van Gelder M, de Wreede LC, Schetelig J, van Biezen A, Volin L, Maertens J, Robin M, Petersen E, de Witte T, Kröger N; EBMT Chronic Malignancies Working Party.

Leukemia. 2013 Apr;27(4):879-88

10. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice.

Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A, Dazzi F, Dreger P, Duarte R, Finke J, Garderet L, Greinix H, Holler E, Kröger N, Lawitschka A, Mohty M, Nagler A, Passweg J, Ringdén O, Socié G, Sierra J, Sureda A, Wiktor-Jedrzejczak W, Madrigal A, Niederwieser D.

Bone Marrow Transplant. 2013 Jul 29. doi: 10.1038/bmt.2013.107. [Epub ahead of print]



CMWP Business Meeting held in Paris, France (2012)

Presentations at ASH 2013 (New Orleans) from CMWP

ORAL

Center Experience and Calendar Year Of Transplantation Strongly Influence Short Term Survival After Autologous Peripheral Blood Transplantation In 1315 Patients With Light Chain Amyloidosis: An EBMT Analysis

Number: 417

Presenter: **Stefan Schonland**

Session: 731. Clinical Allogeneic and Autologous Transplantation - Results: Autologous Transplantation for Lymphoma, Myeloma and APL

Time and Location: Monday, Dec 9, 2013: 10:30 AM-12:00 PM, 208-210 (Ernest N. Morial Convention Center)

Impact Of Conditioning Regimen, Donor Source, and DIPSS Score On Outcome Of Allogeneic Hematopoietic Stem Cell Transplantation For Myelofibrosis

Number: 712

Presenter: **Nicolaus Kröger**

Session: 731. Clinical Allogeneic and Autologous Transplantation - Results: Matched Related or Unrelated Donor Transplantation

Time and Location: Monday, Dec 9, 2013: 4:30 PM-6:00 PM, 208-210 (Ernest N. Morial Convention Center)

Reduced Intensity Allogeneic Stem Cell Transplant In Patients With Multiple Myeloma: A Comparison Of Planned Autologous-Reduced Intensity Allogeneic Stem Cell Transplant (Auto-Allo) and Reduced Intensity Allogeneic Stem Cell Transplant (RIC) As Upfront Transplant In Patients With Multiple Myeloma, An EBMT Analysis

Number: 920

Presenter: **Firoozeh Sahebi**

Session: 731. Clinical Allogeneic and Autologous Transplantation - Results: Allogeneic Transplantation

Time and Location: Tuesday, Dec 10, 2013: 7:30 AM-9:00 AM, 208-210 (Ernest N. Morial Convention Center)

The Role Of High Dose Chemotherapy and Autologous Stem Cell Transplantation (ASCT) In Patients With POEMS Syndrome: A Retrospective study Of The Plasma Cell Disorders Subcommittee Of The Chronic Malignancy Working Party Of The EBMT

Number: 415

Presenter: **Gordon Cook**

Session: 731. Clinical Allogeneic and Autologous Transplantation - Results: Autologous Transplantation for Lymphoma, Myeloma and APL

Time and Location: Monday, Dec 9, 2013: 10:30 AM-12:00 PM, 208-210 (Ernest N. Morial Convention Center)

The Revised IPSS (IPSS-R) At Transplant Predicts Overall and Relapse-Free Survival After Allogeneic Stem Cell Transplantation In MDS/sAML: A Retrospective Analysis Of The EBMT Chronic Malignancies Working Party

Number: 922

Presenter: **Christof Scheid**

Session: 731. Clinical Allogeneic and Autologous Transplantation - Results: Allogeneic Transplantation

Time and Location: Tuesday, Dec 10, 2013: 7:30 AM-9:00 AM, 208-210 (Ernest N. Morial Convention Center)

POSTER

Outcomes After Unrelated Cord Blood Transplantation For Adults With Primary Or Secondary Myelofibrosis: A Retrospective Study On Behalf Of Eurocord and Chronic Malignancy Working Party-EBMT

Number: 2156

Presenter: **Marie Robin**

Session: 731. Clinical Allogeneic and Autologous Transplantation - Results: Poster I

Time and Location: Saturday, Dec 7, 2013: 5:30 PM-7:30 PM, Hall G (Ernest N. Morial Convention Center)

Prognostic Value Of Five-Group Cytogenetic Risk Classification In Patients With MDS After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Multicenter Study Of The Chronic Malignancies Working Party Of The EBMT

Number: 2092

Presenter: **Christian Koenecke**

Session: 731. Clinical Allogeneic and Autologous Transplantation - Results: Poster I

Time and Location: Saturday, Dec 7, 2013: 5:30 PM-7:30 PM Hall G (Ernest N. Morial Convention Center)

Quality Of Life After Allogeneic Stem Cell Transplantation In Pati-

ents With Myelofibrosis (CMWP of EBMT)

Number: 2974

Presenter: **Nicolaus Kröger**

Session: 901. Health Services and Outcomes Research: Poster II

Time and Location:

Sunday, Dec 8, 2013: 6:30 PM-8:30 PM, Hall E (Ernest N. Morial Convention Center)

The Kinetic Of Bone Marrow Fibrosis Regression Predicts Outcome In Myelofibrosis Patients After Allogeneic SCT

Number: 2078

Presenter: **Nicolaus Kröger**

Session: 723. Clinical Allogeneic and Autologous Transplantation - Late Complications and Approaches to Disease Recurrence: Poster I

Time and Location: Saturday, Dec 7, 2013: 5:30 PM-7:30 PM, Hall G (Ernest N. Morial Convention Center)

Comparison Of Unrelated Cord Blood (CB) and Peripheral Blood Stem Cell (PB) Transplantation In Adults With Myelodysplastic Syndrome (MDS) After Reduced Intensity Conditioning Regimen (RIC): A Collaborative Study From Eurocord and Chronic Malignancies Working Party (CMWP-EBMT)

Number: 3334

Presenter: **Marie Robin**

Session: 731. Clinical Allogeneic and Autologous Transplantation - Results: Poster II

Time and Location: Sunday, Dec 8, 2013: 6:30 PM-8:30 PM, Hall G (Ernest N. Morial Convention Center)

Comparison Of Intensive Chemotherapy and Hypomethylating Agents Prior To Allogeneic Stem Cell Transplantation For Advanced MDS (RAEB, RAEB-T). A Study Of The MDS Subcommittee Of The

CMWP Of EBMT

Number: 2121

Presenter: **Victoria Potter**

Session: 731. Clinical Allogeneic and Autologous Transplantation - Results: Poster I

Time and Location: Saturday, Dec 7, 2013: 5:30 PM-7:30 PM, Hall G (Ernest N. Morial Convention Center)

EBMT Prospective Non-Interventional Study On Allogeneic Hematopoietic Stem Cell Transplantation In T-Prolymphocytic Leukemia (T-PLL). Preliminary Analysis Of 43 Patients

Number: 3336

Presenter: **Wieslaw Jedrzejczak**

Session: 731. Clinical Allogeneic and Autologous Transplantation - Results: Poster II

Time and Location: Sunday, Dec 8, 2013: 6:30 PM-8:30 PM, Hall G (Ernest N. Morial Convention Center)

Data management, statistician and subcommittees of CMWP



Anja van Biezen
Data Management




Simona Iacobelli
Statistician



Liesbeth de Wreede
Statistician




Johannes Schetelig
SC Chronic Lymphocytic Leukemia



Theo de Witte
SC Myelodysplastic Syndrome



Eduardo Olavarria
SC Myeloproliferative Neoplasms



Laurent Garderet
SC Plasmacell-Disorders